By Giulia Petroni

Novartis said that the U.S. Food and Drug Administration has classified the Pluvicto drug shortage status as resolved, and that supply availability should continue to increase into 2024.

Pluvicto is an intravenous radioligand therapy approved in the U.S., the EU and other countries to treat adults with advanced prostate cancer who have already been treated with other anti-cancer treatments.

"We have been working hard to increase the capacity and improve the reliability of the supply of our radioligand therapies to ensure patients have access to this therapy and to prepare for future growth as more patients may become eligible for this treatment," said Victor Bulto, president of Novartis U.S.

The Swiss pharmaceutical giant said late on Thursday that weekly production capacity has more than doubled since May and that it is working to further expand production lines at its sites.

Write to Giulia Petroni at giulia.petroni@wsj.com

(END) Dow Jones Newswires

October 27, 2023 01:30 ET (05:30 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Grafico Azioni Novartis (NYSE:NVS)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Novartis
Grafico Azioni Novartis (NYSE:NVS)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Novartis